Bronchopulmonary Dysplasia Pipeline Analysis Report 2026

Report Coverage

The Bronchopulmonary Dysplasia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bronchopulmonary dysplasia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bronchopulmonary dysplasia. The bronchopulmonary dysplasia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bronchopulmonary dysplasia Pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Bronchopulmonary Dysplasia treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bronchopulmonary dysplasia.

Read more about this report - Request a Free Sample

Bronchopulmonary Dysplasia Pipeline Outlook

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants who require prolonged oxygen therapy or mechanical ventilation support. It occurs due to incomplete lung development combined with inflammation and injury to delicate lung tissues, leading to impaired alveolar growth, reduced lung function, and long-term respiratory complications. Pulmonary hypertension neonates is a common associated condition that can further worsen outcomes.

Bronchopulmonary dysplasia treatment focuses on improving respiratory function, minimizing lung injury, and supporting lung development. Management includes oxygen supplementation, corticosteroid therapy NICU, diuretics, nutritional support, and Vitamin A Supplementation. Emerging approaches such as stem cell therapy BPD are being investigated to enhance lung repair and improve long-term clinical outcomes. In August 2025, Airway Therapeutics received European Medicines Agency Pediatric Committee approval for the Pediatric Investigation Plan of zelpultide alfa, a recombinant human surfactant protein D therapy for preventing Bronchopulmonary Dysplasia in very preterm infants. The candidate entered a pivotal Phase 2b/3 study, targeting inflammation modulation, pathogen clearance, and improved pulmonary function, strengthening the pipeline and advancing innovative treatment options.

Bronchopulmonary Dysplasia Epidemiology

The pipeline is gaining attention due to the increasing incidence of bronchopulmonary dysplasia (BPD) among premature infants worldwide. According to the American Lung Association, approximately 10,000 to 15,000 newborns develop BPD in the United States each year, highlighting a significant unmet medical need. The increasing incidence of preterm births and advancements in neonatal care are driving research and development activities in the bronchopulmonary dysplasia treatment pipeline. Ongoing clinical studies are focused on improving lung function, reducing disease severity, and enhancing long-term outcomes, supporting future growth in the BPD drug development landscape.

Bronchopulmonary Dysplasia – Pipeline Therapeutic Assessment

Bronchopulmonary Dysplasia Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total bronchopulmonary dysplasia clinical trials, holds around 49% share with strong clinical evaluation activity. It is followed by phase I at 28%, with increasing safety and dose-optimization studies. Phase III accounts for 15% with advanced efficacy validation, phase IV represents 5% with post-marketing evidence generation, and early phase I contributes 3% with innovative pipeline exploration. Collectively, these phases support positive growth.

Bronchopulmonary Dysplasia Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the bronchopulmonary dysplasia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The bronchopulmonary dysplasia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bronchopulmonary dysplasia. Immune-modulating biologics are emerging as promising therapeutic options in the bronchopulmonary dysplasia drug pipeline. For instance, zelpultide alfa, a recombinant human surfactant protein D, is under Phase III evaluation for the prevention of bronchopulmonary dysplasia in very preterm infants. The therapy aims to reduce pulmonary inflammation, enhance immune defense, and protect immature lungs, thereby lowering disease severity and improving neonatal respiratory outcomes.

Bronchopulmonary Dysplasia Clinical Trials – Key Players

The EMR report for the bronchopulmonary dysplasia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bronchopulmonary dysplasia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bronchopulmonary dysplasia clinical trials:

• OHB Neonatology Ltd.
• Medipost Co Ltd.
• Airway Therapeutics, Inc.
• Meridigen Biotech Co., Ltd.
• EXO Biologics S.A.
• The Emmes Company, LLC
• Mallinckrodt
• Merck Sharp & Dohme LLC
• Chiesi Farmaceutici S.p.A.

Bronchopulmonary Dysplasia – Emerging Drugs Profile

Key Questions Answered in the Bronchopulmonary Dysplasia Pipeline Insight Report

• Which companies/institutions are leading the bronchopulmonary dysplasia drug development?
• Which company is leading the bronchopulmonary dysplasia pipeline development activities?
• What is the current bronchopulmonary dysplasia commercial assessment?
• What are the opportunities and challenges present in the bronchopulmonary dysplasia pipeline landscape?
• What is the efficacy and safety profile of bronchopulmonary dysplasia pipeline drugs?
• Which company is conducting major trials for bronchopulmonary dysplasia drugs?
• Which companies/institutions are involved in bronchopulmonary dysplasia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in bronchopulmonary dysplasia?

Reasons To Buy This Report

The bronchopulmonary dysplasia pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for bronchopulmonary dysplasia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bronchopulmonary dysplasia collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Respiratory Care Device Market

Respiratory Health Supplements Market